Pre-Hospital Use of Plasma for Traumatic Hemorrhage

Phase 2

Withdrawn

• Conditions: Shock, Hemorrhagic
• Interventions: Drug: Normal saline; Biological: Plasma

• Registration Number: NCT02303964
• Lead Sponsor: Virginia Commonwealth University

Brief Summary

Type A Thawed Plasma (TP) will be compared in polytrauma patients who receive only Normal Saline (NS) (standard of care) before arrival at the hospital.

The purpose of this study is to determine if prehospital administration of thawed plasma can reduce mortality of patients who have lost a large amount of blood due to their injuries, compared to those receiving standard of care.

Detailed Description

INVESTIGATIONAL PLAN This will be an open-label, non-blinded, randomized clinical trial to investigate mortality (30 days) and morbidity of Type A thawed Plasma (TP) versus NS infusion at earliest contact, administered by Emergency Medical Service (EMS) supervisors to subjects who have sustained severe Polytrauma / Major hemorrhage (PTr / MH). The total study is expected to last 2 years with 210 patients enrolled.

The two EMS agencies involved in the study will each have one EMS supervisor quick-response vehicle (QRV) equipped with an approved, validated refrigeration unit for TP transport. EMS personnel trained in plasma administration and recognition of reactions may administer up to 2 units of TP to subjects approved for study enrollment. Blood samples for coagulation and lipid testing will be drawn prior to TP administration by EMS personnel,and repeated by hospital personnel at 30 minutes, 8 hours, and 24 hours post-injury.

This study is approved for "Exception from Informed Consent" (EFIC). Once the patient has reached VCUMC and has been entered into the VCUMC health care system, the treating team will advise the Study Coordinator (SC) whether or not a subject is able to consent. As the plasma administration will occur in the field prior to arrival to VCUMC, the SC will make every effort possible to obtain consent from the subject or legally authorized representative (LAR) for continued study participation before the next intervention (8 hour blood specimen collection). The attempts to contact the LAR will be documented in detail. If a subject lacks the ability to provide his/her own consent by the end of day 30, the consent signed by the LAR will be the consent document in force at the subject's completion of the study and no further consent will be sought.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2014-10-06
• Study Start: 2014-11
• Study First Submitted QC: 2014-11-28
• Study First Posted: 2014-12-01
• Primary Completion: 2016-01
• Study Completion: 2016-01
• Status Verified: 2016-02
• Last Update Submitted: 2016-02-19
• Last Update Posted: 2016-02-23

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Blunt or penetrating trauma,
• Blood Pressure (BP) systolic <70 mmHg or BP 70-90 mmHg with Heart Rate (HR) > 108 Beats Per Minute (BPM),
• Ongoing hemorrhage with unstable vital signs

Read More

Exclusion Criteria

• Wearing opt-out wrist band,
• Wearing medical alert jewelry / bracelet, etc. indicating Jehovah Witness or similar with objections to blood transfusions,
• Refusal to participate (by subject or LAR),
• Communication barrier at the time of eliciting refusal (non-English speaking or non-Spanish speaking),
• Not expected to survive transport to Virginia Commonwealth University Medical Center (VCUMC),
• Documented Do Not Resuscitate (DNR) order found,
• Cardiac arrest or Cardio-Pulmonary Resuscitation (CPR) prior to randomization
• Penetrating head trauma,
• Known / obvious pregnancy,
• Prisoner,
• Burns > 20% of body surface

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Normal saline	Normal saline	Eligible subjects with polytrauma (PT) and major hemorrhage (MH) will be randomized to receive normal saline in the pre-hospital setting administered by EMS first responders. Normal saline is standard of care
Type A Thawed Plasma	Plasma	Eligible subjects with polytrauma (PT) and major hemorrhage (MH) will be randomized to receive 2 units of thawed Type A plasma in the pre-hospital setting administered by EMS first responders. An exception from informed consent under 21CFR 50.24 is required since enrollment will occur (for the majority of subjects) before consent can be obtained.

Primary Outcome Measures

Name	Time	Method
Mortality	30 day	all cause mortality

Secondary Outcome Measures

Name	Time	Method
Hematology (Hemoglobin, hematocrit)	24 hours	Hemoglobin, hematocrit
Lipidomic profiles (arachidonic acid, eicosinoid expression, prostacyclin expression)	24 hours	arachidonic acid, eicosinoid expression, prostacyclin expression
Coagulation function (thromboelastography, RoTEM, Hemodyne, fibrinogen, D-dimer, PFA-100, platelet count, flow cytometry)	24 hours	thromboelastography, RoTEM, Hemodyne, fibrinogen, D-dimer, PFA-100, platelet count, flow cytometry
Vital signs (blood pressure, pulse, temperature)	24 hours	blood pressure, pulse, temperature
Blood product utilization (number of red blood cell units, number of plasma units, number of platelet units cryoprecipitate doses)	30 days	number of red blood cell units, number of plasma units, number of platelet units cryoprecipitate doses
Blood biochemistry (pH, bicarbonate, lactate)	24 hours	pH, bicarbonate, lactate
Hospital outcomes (number of cases of multi-system organ failure (MSOF), renal failure, length of hospital stay, length of ICU stay, number of days on a ventilator, number of surgeries, number of infections)	30 days	number of cases of multi-system organ failure (MSOF), renal failure, length of hospital stay, length of ICU stay, number of days on a ventilator, number of surgeries, number of infections

Trial Locations

Locations (1)

Virginia Commonwealth University; 🇺🇸 Richmond, Virginia, United States